Quidel Corporation (NASDAQ:QDEL) Director Thomas D. Brown sold 12,154 shares of the company’s stock in a transaction on Tuesday, December 5th. The stock was sold at an average price of $39.62, for a total transaction of $481,541.48. Following the completion of the sale, the director now owns 57,179 shares of the company’s stock, valued at $2,265,431.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Quidel Corporation (NASDAQ:QDEL) traded down $0.11 during midday trading on Thursday, hitting $39.69. 207,632 shares of the stock traded hands, compared to its average volume of 298,705. The company has a debt-to-equity ratio of 0.70, a current ratio of 6.28 and a quick ratio of 5.68. Quidel Corporation has a 12 month low of $18.25 and a 12 month high of $45.55.
Quidel (NASDAQ:QDEL) last posted its quarterly earnings data on Wednesday, November 1st. The company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by ($0.21). The firm had revenue of $50.89 million for the quarter, compared to analyst estimates of $50.47 million. Quidel had a negative return on equity of 2.36% and a negative net margin of 2.33%. The business’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 EPS. equities analysts predict that Quidel Corporation will post 0.6 earnings per share for the current year.
A number of equities research analysts have issued reports on the stock. BidaskClub upgraded shares of Quidel from a “sell” rating to a “hold” rating in a report on Saturday, December 2nd. Zacks Investment Research cut shares of Quidel from a “buy” rating to a “hold” rating in a report on Tuesday, November 7th. Piper Jaffray Companies restated a “buy” rating and set a $50.00 price target on shares of Quidel in a report on Friday, November 3rd. Barclays increased their target price on shares of Quidel from $45.00 to $49.00 and gave the company an “overweight” rating in a research note on Thursday, November 2nd. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $48.00 target price on shares of Quidel in a research note on Wednesday, October 25th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Quidel currently has an average rating of “Buy” and an average price target of $48.80.
COPYRIGHT VIOLATION NOTICE: “Quidel Corporation (QDEL) Director Sells $481,541.48 in Stock” was reported by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://weekherald.com/2017/12/07/quidel-corporation-qdel-director-sells-481541-48-in-stock.html.
Quidel Company Profile
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.